Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Corvus Pharmaceuticals Inc (CRVS)
NASDAQ:CRVS
Holding CRVS?
Track your performance easily
CRVS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.30 - $10.00
Previous Close$4.99
Volume2.59M
Average Volume (3M)1.07M
Market Cap
$327.07M
Enterprise Value$285.77M
Total Cash (Recent Filing)$41.65M
Total Debt (Recent Filing)$354.00K
Price to Earnings (P/E)―
Beta1.79
Next Earnings
Mar 06, 2025EPS Estimate
-$0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.93
Shares Outstanding64,257,251
10 Day Avg. Volume2,371,500
30 Day Avg. Volume1,073,229
Standard Deviation0.37
R-Squared0.02
Alpha0.05
Financial Highlights & Ratios
Price to Book (P/B)26.26
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-12.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-5.09
Forecast
1Y Price Target
$15.75Price Target Upside215.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Corvus Pharmaceuticals News
PremiumCompany Announcements
Corvus Pharmaceuticals Reports Promising Phase 1 Data and Financial Boost
Ownership Overview
44.05% Insiders
4.70% Mutual Funds
27.41% Other Institutional Investors
19.83% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CRVS FAQ
What was Corvus Pharmaceuticals Inc’s price range in the past 12 months?
Corvus Pharmaceuticals Inc lowest stock price was $1.30 and its highest was $10.00 in the past 12 months.
What is Corvus Pharmaceuticals Inc’s market cap?
Currently, no data Available
When is Corvus Pharmaceuticals Inc’s upcoming earnings report date?
Corvus Pharmaceuticals Inc’s upcoming earnings report date is Mar 06, 2025 which is in 75 days.
How were Corvus Pharmaceuticals Inc’s earnings last quarter?
Corvus Pharmaceuticals Inc released its earnings results on Nov 12, 2024. The company reported -$0.6 earnings per share for the quarter, missing the consensus estimate of -$0.11 by -$0.49.
Is Corvus Pharmaceuticals Inc overvalued?
According to Wall Street analysts Corvus Pharmaceuticals Inc’s price is currently Undervalued.
Does Corvus Pharmaceuticals Inc pay dividends?
Corvus Pharmaceuticals Inc does not currently pay dividends.
What is Corvus Pharmaceuticals Inc’s EPS estimate?
Corvus Pharmaceuticals Inc’s EPS estimate is -$0.12.
How many shares outstanding does Corvus Pharmaceuticals Inc have?
Corvus Pharmaceuticals Inc has 64,257,250 shares outstanding.
What happened to Corvus Pharmaceuticals Inc’s price movement after its last earnings report?
Corvus Pharmaceuticals Inc reported an EPS of -$0.6 in its last earnings report, missing expectations of -$0.11. Following the earnings report the stock price went up 2.071%.
Which hedge fund is a major shareholder of Corvus Pharmaceuticals Inc?
Among the largest hedge funds holding Corvus Pharmaceuticals Inc’s share is Towerview Llc. It holds Corvus Pharmaceuticals Inc’s shares valued at 620K.
---
Corvus Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.75 (215.63% Upside)
$15.75 (215.63% Upside)
Blogger Sentiment
Bullish
CRVS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 282.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 1.1%
Last 30 Days ▼ 1.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
219.87%
12-Months-Change
Fundamentals
Return on Equity
-200.48%
Trailing 12-Months
Asset Growth
13.23%
Trailing 12-Months
Company Description
Corvus Pharmaceuticals Inc
Corvus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of oncology therapies. The company focuses on disabling cancer's ability to subvert immune attack by inhibiting adenosine in the tumor microenvironment and by blocking its production by tumors. Its product pipeline includes Adenosine A2A Receptor Antagonist CPI-444, Adenosine Production Inhibitor Anti-CD73, Adenosine A2B Receptor Antagonist, ITK Inhibitor, and Myeloid Cell Suppression. The company was founded by Richard A. Miller, Peter A. Thompson, and Joseph J. Buggy on January 27, 2014 and is headquartered in Burlingame, CA.
---
CRVS Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in clinical trials and strategic partnerships, particularly for soquelitinib across various indications. However, financial challenges were evident with a substantial increase in net loss due to warrant liabilities.Read More>---
CRVS Stock 12 Month Forecast
Average Price Target
$15.75
▲(215.63% Upside)
Technical Analysis
Best Analysts Covering CRVS
1 Year
1 Year Success Rate
6/8 ratings generated profit
1 Year Average Return
+130.30%
reiterated a buy rating 3 days ago
Copying Jeff Jones's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +130.30% per trade.
---